Literature DB >> 20151845

Emerging MEK inhibitors.

James A McCubrey1, Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo, Roger Ove, Michele Milella, Agostino Tafuri, Paolo Lunghi, Antonio Bonati, Franca Stivala, Ferdinando Nicoletti, Massimo Libra, Alberto M Martelli, Giuseppe Montalto, Melchiorre Cervello.   

Abstract

IMPORTANCE OF THE FIELD: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. AREAS COVERED BY THIS REVIEW: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. WHAT THE READER WILL GAIN: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. TAKE HOME MESSAGE: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151845     DOI: 10.1517/14728210903282760

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  27 in total

1.  Biology using engineering tools: the negative feedback amplifier.

Authors:  Marc R Birtwistle; Walter Kolch
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

2.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

Review 3.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

Review 4.  Immunological hurdles of ageing: indispensable research of the human model.

Authors:  Abbe N Vallejo
Journal:  Ageing Res Rev       Date:  2011-02-21       Impact factor: 10.895

5.  Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.

Authors:  Lindsey N Micel; John J Tentler; Aik-Choon Tan; Heather M Selby; Kelsey L Brunkow; Kelli M Robertson; S Lindsey Davis; Peter J Klauck; Todd M Pitts; Esha Gangolli; Robyn Fabrey; Shawn M O'Connell; Patrick W Vincent; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2014-11-05       Impact factor: 6.261

6.  Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.

Authors:  Jerry A Saunders; LeAnn C Rogers; Chananat Klomsiri; Leslie B Poole; Larry W Daniel
Journal:  Free Radic Biol Med       Date:  2010-10-08       Impact factor: 7.376

7.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

8.  CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.

Authors:  Dong Joon Kim; Mee-Hyun Lee; Kanamata Reddy; Yani Li; Do Young Lim; Hua Xie; Sung-Young Lee; Young Il Yeom; Ann M Bode; Zigang Dong
Journal:  Carcinogenesis       Date:  2013-01-25       Impact factor: 4.944

9.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Authors:  Piro Lito; Anna Saborowski; Jingyin Yue; Martha Solomon; Eric Joseph; Sunyana Gadal; Michael Saborowski; Edward Kastenhuber; Christof Fellmann; Kazuhiro Ohara; Kenji Morikami; Takaaki Miura; Christine Lukacs; Nobuya Ishii; Scott Lowe; Neal Rosen
Journal:  Cancer Cell       Date:  2014-04-17       Impact factor: 31.743

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.